

## List of publications

---

### Original Articles

#### Basic Research

Multi-chamber electroosmosis using textile reinforced agar membranes - A promising concept for the future of hemodialysis. Kofler M, Lenninger M, Mayer G, Neuwirt H, Grimm M, Bechtold T. *Carbohydr Polym*. 2016 Jan 20;136:81-6. doi: 10.1016/j.carbpol.2015.09.013. Epub 2015 Sep 8.

Ofer P, Heidegger I, Eder IE, Schöpf B, Neuwirt H, Geley S, Helmut K, Massoner P. Both IGF1R and INSR knockdown exert anti-tumorigenic effects in prostate cancer in vitro and in vivo. *Mol Endocrinol*. 2015 Oct 9:me20151073. [Epub ahead of print] PubMed PMID: 26452103.

Puhr M, Hoefler J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. *Oncogene*. 2015 Aug 10. doi: 10.1038/onc.2015.292. [Epub ahead of print] PubMed PMID: 26257066.

Rudnicki M, Beckers A, Neuwirt H, Vandesompele J. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy. *Nephrol Dial Transplant*. 2015 Aug;30 Suppl 4:iv35-42. doi: 10.1093/ndt/gfv079. PubMed PMID: 26209736.

Neuwirt H, Wabnig E, Feistritzer C, Eder IE, Salvador C, Puhr M, Culig Z, Massoner P, Tiefenthaler M, Steurer M, Konwalinka G. Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines in vitro and in vivo. *PLoS One*. 2015 Feb 13;10(2):e0117806. doi: 10.1371/journal.pone.0117806. eCollection 2015. PubMed PMID: 25680181; PubMed Central PMCID: PMC4334520.

Neuwirt H, Perco P, Kainz A, Mühlberger I, Leierer J, Braniff SJ, Mayer B, Mayer G, Rudnicki M. A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases. *BMC Med Genomics*. 2014 Dec 24;7:75. doi: 10.1186/s12920-014-0075-8. PubMed PMID: 25540021; PubMed Central PMCID: PMC4301948.

Puhr M, Hoefler J, Neuwirt H, Eder IE, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. *Oncotarget*. 2014 Dec 15;5(23):12043-56. PubMed PMID: 25474038; PubMed Central PMCID: PMC4322998.

Eder IE, Egger M, Neuwirt H, Seifarth C, Maddalo D, Desiniotis A, Schäfer G, Puhr M, Bektic J, Cato AC, Klocker H. Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type  $\alpha$  of protein kinase a in vivo. *Int J Mol Sci*. 2013 Jun 4;14(6):11942-62. doi: 10.3390/ijms140611942. PubMed PMID: 23736698; PubMed Central PMCID: PMC3709765.

Neuwirt H, Eder IE, Puhr M, Rudnicki M. SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent manner. *Lab Invest*. 2013 Jan;93(1):123-34. doi: 10.1038/labinvest.2012.154. Epub 2012 Oct 29. PubMed PMID: 23108375.

Puhr M, Hoefler J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z. Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205. *Am J Pathol*. 2012 Oct 3. doi:pii: S0002-9440(12)00653-0. 10.1016/j.ajpath.2012.08.011. [Epub ahead of print]

Rudnicki M, Perco P, Neuwirt H, Noppert SJ, Leierer J, Sunzenauer J, Eder S, Zoja C, Eller K, Rosenkranz AR, Müller GA, Mayer B, Mayer G. Increased renal versican expression is

associated with progression of chronic kidney disease. *PLoS One*. 2012;7(9):e44891. Epub 2012 Sep 14.

Bouchal J, Santer FR, Höschele PP, Tomastikova E, Neuwirt H, Culig Z. Transcriptional coactivators p300 and CBP stimulate estrogen receptor-beta signaling and regulate cellular events in prostate cancer. *Prostate* 2010. Mar 1;71(4):431-7. doi: 10.1002/pros.21257. Epub 2010 Sep 21.

Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z. SOCS-3 antagonises the proliferative and migratory effects of FGF-2 in prostate cancer by inhibition of MAPK signalling. *Endocrine Related Cancer*. May 18;17(2):525-38. Print 2010 Jun.

Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z. Androgens stimulate the expression of SOCS-3 and inhibits their effect on proliferation and secretion. *Aktuelle Urol*. 2009 Aug;40(4):231-4. Epub 2009 Jul 24.

Puhr M, Santer FR, Neuwirt H, Kenner L, Susani M, Hobisch A, Culig Z. Down-Regulation of Suppressor of Cytokine Signaling-3 causes Prostate Cancer Cell Death through Activation of the Intrinsic Apoptosis Pathway. *Cancer Res*. 2009, in press

Neuwirt H, Puhr M, Santer F, Susani M, Doppler W, Marcias G, Rauch V, Brugger M, Hobisch A, Kenner L, Culig Z. Suppressor of Cytokine Signaling (SOCS)-1 is Expressed in Human Prostate Cancer and Exerts Growth-inhibitory Function through Down-regulation of Cyclins and Cyclin-dependent Kinases. *Am J Pathol*. 2009 May;174(5):1921-30. Epub 2009 Mar 26.

Malinowska K, Neuwirt H, Cavarretta I, Bektic J, Steiner H, Dietrich H, Moser P, Fuchs D, Hobisch A, Culig Z. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. *Endocrine Relat Cancer*. 2008; Nov 14

Neuwirt H, Arias MC, Puhr M, Hobisch A, Culig Z. Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells. *Prostate*. 2008; 68:1647-54.

Cavarretta IT, Neuwirt H, Zaki MH, Steiner H, Hobisch A, Nemeth JA, Culig Z. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma. *Adv Exp Med Biol*. 2008; 617:547-55.

Gollmann G, Neuwirt H, Tripp CH, Mueller H, Konwalinka G, Heufler C, Romani N, Tiefenthaler M. Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions. *Int Immunol*. 2008 Jul;20(7):911-23. Epub 2008 May 20.

Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. *Endocr Relat Cancer*. 2007 Dec;14(4):1007-19. Erratum in: *Endocr Relat Cancer*. 2008 Mar;15(1):366.

Mitterberger M, Neuwirt H, Cavarretta IT, Hobisch A, Culig Z. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide. *Prostate*. 2007 Aug 1;67(11):1194-201.

Bellezza I\*, Neuwirt H\*, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. *Am J Pathol*. 2006 Dec;169(6):2199-208. \* joint first authors

Cavarretta IT, Neuwirt H, Untergasser G, Moser PL, Zaki MH, Steiner H, Rumpold H, Fuchs D, Hobisch A, Nemeth JA, Culig Z. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. *Oncogene*. 2007 May 3;26(20):2822-32. Epub 2006 Oct 30.

Neuwirt H, Muller H, Cavarretta IT, Tiefenthaler M, Bartsch G, Konwalinka G, Culig Z. Akacid-medical-formulation, a novel biocidal oligoguanidine with antitumor activity reduces S-

phase in prostate cancer cell lines through the Erk 1/2 mitogen-activated protein kinase pathway. *Int J Oncol*. 2006 Aug;29(2):503-12.

Müller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, Mayer G, Konwalinka G, Heufler C, Tiefenthaler M. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. *Eur J Immunol*. 2005 Feb;35(2):533-45.

## **Clinical Research**

Mitterberger M, Pinggera GM, Neuwirt H, Colleselli D, Pelzer A, Bartsch G, Strasser H, Gradl J, Pallwein L, Frauscher F. Do mountain bikers have a higher risk of scrotal disorders than on-road cyclists? *Clin J Sport Med*. 2008 Jan;18(1):49-54.

Mitterberger M, Pinggera GM, Pelzer A, Bartsch G, Colleselli D, Neuwirt H, Gradl J, Pallwein L, Aigner F, Frauscher F, Strasser H. Comparison of the precision of transurethral endoscopic versus ultrasound-guided application of injectables. *BJU Int*. 2008 Jan;101(2):245-9. Epub 2007 Oct 8.

Lunacek A, Schwentner C, Oswald J, Fritsch H, Sergi C, Thomas LN, Rittmaster RS, Klocker H, Neuwirt H, Bartsch G, Radmayr C. Fetal distribution of 5alpha-reductase 1 and 5alpha-reductase 2, and their input on human prostate development. *J Urol*. 2007 Aug;178(2):716-21. Epub 2007 Jun 14.

Mitterberger M, Pallwein L, Gradl J, Frauscher F, Neuwirt H, Leunhartsberger N, Strasser H, Bartsch G, Pinggera GM. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. *BJU Int*. 2007 Apr;99(4):831-5. Epub 2007 Jan 22.

Mitterberger M, Pinggera GM, Maier E, Neuwirt H, Neururer R, Pallwein L, Gradl J, Bartsch G, Strasser H, Frauscher F. Value of 3-dimensional transrectal/transvaginal sonography in diagnosis of distal ureteral calculi. *J Ultrasound Med*. 2007 Jan;26(1):19-27.

Mitterberger M, Pinggera GM, Neuwirt H, Maier E, Akkad T, Strasser H, Gradl J, Pallwein L, Bartsch G, Frauscher F. Three-dimensional ultrasonography of the urinary bladder: preliminary experience of assessment in patients with haematuria. *BJU Int*. 2007 Jan;99(1):111-6. Epub 2006 Oct 11.

## **Reviews**

Samson N, Neuwirt H, Pühr M, Klocker H, Eder IE. In vitro model systems to study androgen receptor signaling in prostate cancer. *Endocrine Relat Cancer*. 2013 Feb;27

Neuwirt H, Mayer G. Nierenbeteiligung bei monoklonalen Leichtkettenerkrankungen. *Der Nephrologe*. *Nephrologe* 2013 · 8:150–155\_ · DOI 10.1007/s11560-012-0717-9

Hellemons ME, Kerschbaum J, Bakker SJ, Neuwirt H, Mayer B, Mayer G, de Zeeuw D, Lambers Heerspink HJ, Rudnicki M. Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. *Diabet Med*. 2012 May;29(5):567-77.

Neuwirt H, Rudnicki M, Schramek H, Mayer G. Monoclonal light chains and the kidney. *Nephrology Reviews* 2011; 3:e3: 13-22

## **Case Reports / Letters**

Kronbichler A, Gut N, Zwerina J, Neuwirt H, Rudnicki M, Mayer G. Extending the spectrum of a chameleon: IgG4-related disease appearing as interstitial nephritis and mimicking anti-

neutrophil cytoplasmic antibody-associated vasculitis. *Rheumatology (Oxford)*. 2015 Oct;54(10):1936-8. doi: 10.1093/rheumatology/kev248. Epub 2015 Jul 9. PubMed PMID: 26163289.

Neuwirt H, Kronbichler A. Dabigatran pharmacokinetics--implications for treatment. *Am J Kidney Dis*. 2013 Jul;62(1):180. doi: 10.1053/j.ajkd.2013.02.382. PubMed PMID: 23773843.

Neuwirt H, Rosenkranz AR. Reply to a letter to the editor concerning the case report "A rare case of milky urine". *Wien Klin Wochenschr*. 2010 Oct;122(23-24):728.

Neuwirt H, Eller P, Tiefenthaler M, Mayer G, Rosenkranz AR. A rare case of milky urine. *Wien Klin Wochenschr*. 2010 Sep 30. 122(19-20):596-600

### **Published Abstracts**

Neuwirt H, Puhr M, Cavarretta I, Mitterberger M, Hobisch A, Culig Z. SOCS-3 is upregulated by androgens in prostate cancer cells and exerts inhibitory effects on AR-mediated proliferation. *BJU Int*. 2007 Sep. 100(3):8

Puhr M, Neuwirt H, Cavarretta I, Hobisch A, Culig Z. SOCS-3 expression is regulated by fibroblast growth factor (FGF)-2 in prostate cancer cell lines. *BJU Int*. 2007 Sep. 100(3):14

Bouchal J, Neuwirt H, Tomastikova E, Culig Z. Effects of coactivator CBP and androgen receptor on estrogen receptor beta in prostate cancer cell lines. *BJU Int*. 2007 Sep. 10(3):34

Mitterberger M, Neuwirt H, Cavarretta I, Hobisch A, Culig Z. Bicalutamide-resistant prostate cancer cells show reduced sensitivity to tumor necrosis factor-related apoptosis-inducing ligand. *European Urology Supplements*. 2007 Mar. 2(6):44

Neuwirt H, Salvador C, Wabnig E, Tiefenthaler M, Culig Z, Konwalinka G, Greil R. Antiproliferative and proapoptotic effects of Akacid-medical-formulation on hematologic cell lines. *Blood*. 2006 Nov. 11(108):172B-173B

Malinowska K, Cavarretta I, Neuwirt H, Fuchs D, Zaki M, Hobisch A, Nemeth J, Culig Z. Interleukin-6 exerts different effects on proliferation and signal transduction in two androgen-sensitive prostate cancer cell lines. *European Urology Supplements*. 2006 Sep. 14(5):791